Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
Pepijn Eijsvogel(Leiden University Medical Center), Jean‐Cosme Dodart(Merritt College), Igor Radanović(Leiden University), Geert Jan Groeneveld(Leiden University Medical Center), Marieke L. de Kam(Centre for Human Drug Research), Lauren Fedor, Philip H. C. Kremer(Leiden University), Hui Jing Yu(Vaxine (Australia)), Luis Concha‐Marambio(Amprion (United States)), Shuang Ding(Chinese Academy of Sciences), Yihua Ma(Amprion (United States)), Dario Mirski(Tris Pharma (United States)), Maurits F. J. M. Vissers(Centre for Human Drug Research), Mohammad Shahnawaz(Jamia Millia Islamia), Carly M. Farris(Amprion (United States)), Pinaki Misra(Mayo Clinic in Arizona), Wolfgang Singer(Mayo Clinic in Arizona), Ghazal Shareghi, Yu Sun(En Chu Kong Hospital), Justin D. Boyd(Pfizer (United States)), Yueh-Ting Hsieh, Madeline M. Vroom(Kennedy Space Center)
Cited by 38
Related Papers
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
|Nature Neuroscience|2002|858
Optimizing the Cell Painting assay for image-based profiling
|Nature Protocols|2023|156
Joint sequencing of human and pathogen genomes reveals the genetics of pneumococcal meningitis
|Nature Communications|2019|121
JUMP Cell Painting dataset: morphological impact of 136,000 chemical and genetic perturbations
|bioRxiv (Cold Spring Harbor Laboratory)|2023|101
A critique of the second consensus criteria for multiple system atrophy
|Movement Disorders|2019|92